Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study.
Activity-based costing
CAR-T
Cost impact
Italy
Organisational impact
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
22 Jan 2024
22 Jan 2024
Historique:
received:
19
04
2023
accepted:
05
12
2023
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. The literature has focused on their assessment, appraisal and market access solutions. No evidence on the costs sustained to implement CAR-T is available and a few studies reported the cost of the CAR-T clinical pathway, including the activities that are remunerated through inpatient or outpatient fee-for-service/episode. This paper aims at filling the information gap, assessing the cost of implementing CAR-T activity and the full cost of managing the CAR-T clinical pathway. Cost analysis relied on the Activity Based Costing approach, which was applied to two Italian healthcare organisations, both CAR-T Centres authorized by the regional governments with a minimum of 20 patients treated with the first two CAR-T therapies launched on the market. The cost of implementing CAR-T was estimated at €1.31 million (calculated for one of the organizations with complete data). Most of these costs (77%) were generated by quality assurance activity. The mean cost per patient entering the CAR-T pathway (59 and 27) and surviving at follow-up (21 and 5) ranges from €48K to €57K and from €96K to €106K, respectively. Fees for hospitalization and infusion of gene therapy accounts for more than 70% of these costs. The actual hospitalisation cost varies greatly across patients and is in general lower than the fee-for-episode paid by the region to the hospital. Despite its limitations (exploratory nature; the time spent by staff on activities which are not remunerated through fees was estimated through interviews with the CAR-T coordinators; cost items are not fully comparable), this research highlighted the relevant organisational and economic impact of CAR-T and provided important insights for policy makers and healthcare managers: the necessity to invest resources in CAR-T implementation; the need for assessing activities which are not remunerated through fees for service / episode; the opportunity to shift from fee-for-episode / service to bundled payments for CAR-T clinical pathway.
Sections du résumé
BACKGROUND
BACKGROUND
Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. The literature has focused on their assessment, appraisal and market access solutions. No evidence on the costs sustained to implement CAR-T is available and a few studies reported the cost of the CAR-T clinical pathway, including the activities that are remunerated through inpatient or outpatient fee-for-service/episode. This paper aims at filling the information gap, assessing the cost of implementing CAR-T activity and the full cost of managing the CAR-T clinical pathway.
METHODS
METHODS
Cost analysis relied on the Activity Based Costing approach, which was applied to two Italian healthcare organisations, both CAR-T Centres authorized by the regional governments with a minimum of 20 patients treated with the first two CAR-T therapies launched on the market.
RESULTS
RESULTS
The cost of implementing CAR-T was estimated at €1.31 million (calculated for one of the organizations with complete data). Most of these costs (77%) were generated by quality assurance activity. The mean cost per patient entering the CAR-T pathway (59 and 27) and surviving at follow-up (21 and 5) ranges from €48K to €57K and from €96K to €106K, respectively. Fees for hospitalization and infusion of gene therapy accounts for more than 70% of these costs. The actual hospitalisation cost varies greatly across patients and is in general lower than the fee-for-episode paid by the region to the hospital.
CONCLUSIONS
CONCLUSIONS
Despite its limitations (exploratory nature; the time spent by staff on activities which are not remunerated through fees was estimated through interviews with the CAR-T coordinators; cost items are not fully comparable), this research highlighted the relevant organisational and economic impact of CAR-T and provided important insights for policy makers and healthcare managers: the necessity to invest resources in CAR-T implementation; the need for assessing activities which are not remunerated through fees for service / episode; the opportunity to shift from fee-for-episode / service to bundled payments for CAR-T clinical pathway.
Identifiants
pubmed: 38254079
doi: 10.1186/s12913-023-10443-5
pii: 10.1186/s12913-023-10443-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121Informations de copyright
© 2023. The Author(s).
Références
Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689–702.
doi: 10.1097/CJI.0b013e3181ac6138
pubmed: 19561539
pmcid: 2747302
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Sci Transl Med. 2011;3(95):95ra73.
doi: 10.1126/scitranslmed.3002842
pubmed: 21832238
pmcid: 3393096
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid Leukemia. N Engl J Med. 2013;368(16):1509–18.
doi: 10.1056/NEJMoa1215134
pubmed: 23527958
pmcid: 4058440
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545–54.
doi: 10.1056/NEJMoa1708566
pubmed: 29226764
pmcid: 5788566
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell Lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.
doi: 10.1016/S1470-2045(18)30864-7
pubmed: 30518502
Jacobson C, Locke FL, Ghobadi A, et al. Long-term (≥ 4 year and ≥ 5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell Lymphoma (LBCL). Blood. 2021;138:1764–7.
doi: 10.1182/blood-2021-148078
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10. PMID: 34516954.
Forum ATMP. Quinto Report Italiano sulle ATMP ( https://www.atmpforum.com/report/ ). Accessed: March 2023.
Saez-Ibañez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21(9):631–2.
doi: 10.1038/d41573-022-00095-1
pubmed: 35650421
Jönsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JG, Wong O. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ. 2019;20(3):427–38.
doi: 10.1007/s10198-018-1007-x
pubmed: 30229376
Garrison LP, Jackson T, Paul D, Kenston M. Value-based pricing for emerging Gene therapies: the Economic Case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019;25(7):793–9.
pubmed: 30784347
Drummond MF, Neumann PJ, Sullivan SD, Fricke FU, Tunis S, Dabbous O, Toumi M. Analytic considerations in applying a General Economic evaluation reference case to Gene Therapy. Value Health. 2019;22(6):661–8.
doi: 10.1016/j.jval.2019.03.012
pubmed: 31198183
Coyle D, Durand-Zaleski I, Farrington J, Garrison L, von der Graf JM, Greiner W, Longworth L, Meunier A, Moutié AS, Palmer S, Pemberton-Whiteley Z, Ratcliffe M, Shen J, Sproule D, Zhao K, Shah K. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur J Health Econ. 2020;21(9):1421–37.
doi: 10.1007/s10198-020-01212-w
pubmed: 32794011
Gonçalves E. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment. Eur J Health Econ. 2020;21(3):311–20.
doi: 10.1007/s10198-019-01147-x
pubmed: 31919703
pmcid: 7188714
Angelis A, Naci H, Hackshaw A. Recalibrating Health Technology Assessment methods for cell and gene therapies. PharmacoEconomics. 2020;38(12):1297–308.
doi: 10.1007/s40273-020-00956-w
pubmed: 32960434
Ronco V, Dilecce M, Lanati E, Canonico PL, Jommi C. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? J Pharm Policy Pract. 2021;14(1):30.
doi: 10.1186/s40545-021-00311-0
pubmed: 33741076
pmcid: 7980570
Gonçalves E. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. Eur J Health Econ. 2022;23(2):155–63.
doi: 10.1007/s10198-021-01276-2
pubmed: 34106364
Tunis S, Hanna E, Neumann PJ, Toumi M, Dabbous O, Drummond M, Fricke FU, Sullivan SD, Malone DC, Persson U, Chambers JD. Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. Health Policy. 2021;125(12):1550–6.
doi: 10.1016/j.healthpol.2021.10.003
pubmed: 34763929
Drummond M, Ciani O, Fornaro G, Jommi C, Dietrich ES, Espin J, Mossman J, de Pouvourville G. How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? BMC Health Serv Res. 2023;23(1):484.
doi: 10.1186/s12913-023-09494-5
pubmed: 37179322
pmcid: 10182681
Jørgensen J, Hanna E, Kefalas P. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy. 2020;8(1):1715536.
doi: 10.1080/20016689.2020.1715536
pubmed: 32082514
pmcid: 7006635
Jørgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med. 2021;16(4):405–22.
doi: 10.2217/rme-2020-0169
pubmed: 33847163
Jommi C, Bramanti S, Pani M, Ghirardini A, Santoro A. CAR-T-Cell therapies in Italy: Patient Access barriers and recommendations for Health System solutions. Front Pharmacol. 2022;13:915342.
doi: 10.3389/fphar.2022.915342
pubmed: 35837293
pmcid: 9275825
Forum ATMP. Sesto Report Italiano sulle ATMP ( https://www.atmpforum.com/report/ ). Accessed: November 2023.
Canales Albendea MÁ, Canonico PL, Cartron G, Deiters B, Jommi C, Marks R, Rioufol C, Sancho Cia JM, Santoro A, Wagner-Drouet EM. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries. Front Med (Lausanne). 2023;10:1128295.
doi: 10.3389/fmed.2023.1128295
pubmed: 37324138
Ghanem B, Shi L. The Economic Burden of CAR-T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US. BioDrugs (2022) 36:773–780.
Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM, Forman HP, Huntington SF. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular Lymphoma. Blood Adv. 2023;7(5):801–10.
doi: 10.1182/bloodadvances.2022008097
pubmed: 36342852
Jagannath S, Joseph N, Crivera C, Kharat A, Jackson CC, Valluri S, Cost P, Phelps H, Slowik R, Klein T, Smolen L, Yu X, Cohen AD. Component costs of CAR-T therapy in Addition to Treatment Acquisition costs in patients with Multiple Myeloma. Oncol Ther. 2023;11(2):263–75.
doi: 10.1007/s40487-023-00228-5
pubmed: 37014590
pmcid: 10260711
Chihara D, Liao L, Tkacz J, Franco A, Lewing B, Kilgore KM, Nastoupil LJ, Chen L. Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell Lymphoma. Blood. 2023;142(12):1047–55.
doi: 10.1182/blood.2023020197
pubmed: 37339585
Kron F, Franz J, Kron A, Hallek M. Ökonomie Und Management Bei Der CAR-T-Zell-Therapie. Status quo und ausblick [Economics and management CAR T-cell therapy status quo and outlook] Internist 2021 · 62:620–6.
Huguet M, Raimond V, Kaltenbachb E, Augustoa V, Perrierc L. Coût Du séjour Hospitalier lié à L’injection De CAR-T anti-CD19 pour l’Assurance Maladie [How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?]. Bull Cancer. 2021;108(12):1170–80.
doi: 10.1016/j.bulcan.2021.06.005
pubmed: 34561025
Chacim S, Monjardino T, Cunha JL, Medeiros P, Redondo P, Bento MJ, Mariz JM. Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: results from a comprehensive cancer center. PLoS ONE. 2022;17(12):e0278950.
doi: 10.1371/journal.pone.0278950
pubmed: 36490296
pmcid: 9733886
Foglia E, Garagiola E, Ladisa V, Rambaldi A, Cairoli R, Sammassimo S, Salè EO, Zinzani PL, Esposti M, Alberti L, Mulas MF, Melis E, Onnis S, Marcias M, Satta V, Croce D. Multidimensional results and reflections on CAR-T: the Italian evidence. Int J Environ Res Public Health. 2023;20(5):3830.
doi: 10.3390/ijerph20053830
pubmed: 36900841
pmcid: 10001656
Baker JJ. Activity-Based Costing and Activity-Based Management for Healthcare, Aspen Publisher, 1998.
Wright J, Sim, Chris. Research in healthcare: concepts, designs and methods. Cheltenham: N. Thornes; 2002. Reprinted. ed.
Smith MW, Barnett PG. Direct measurement of healthcare costs. Med Care Res Rev. 2003;60(3 Suppl):74S–91S.
doi: 10.1177/1077558703257001
pubmed: 15095547